Abstract
Innovative Partnerships for Drug Discovery against Neglected Diseases
Highlights
Lack of commercial market is often outlined as the main factor for the limited number of drugs against neglected diseases
In the past 10 years, the product research and development (R&D) pipeline, including vaccines, diagnostics, and drugs, for neglected diseases has been supported through product development partnerships (PDPs) and others [1,2,3]
While R&D activities for vaccines and diagnostics for neglected diseases are centered on the identification and evaluation of biomarkers, development of new drugs is presently focused on small molecules with little or no ongoing effort for biopharmaceuticals
Summary
Lack of commercial market is often outlined as the main factor for the limited number of drugs against neglected diseases. In the past 10 years, the product research and development (R&D) pipeline, including vaccines, diagnostics, and drugs, for neglected diseases has been supported through product development partnerships (PDPs) and others [1,2,3].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
